Wolverine Blend Reconstitution: Water, Splits and Units

"Wolverine" is the name sellers and forums give to BPC-157 and TB-500 together, and one way it is sold is a single pre-mixed vial. Reconstituting that vial is the same act as for any peptide vial, but the arithmetic runs twice, once for each peptide, and depends on a split the label often states only as a total. This page works the water volumes, each peptide's concentration and the readings for stated amounts, for the two splits found on pages read on 2026-10-05. What the stack is, and what each peptide's literature holds, is on this site's Wolverine stack page; how the two compare as separate compounds is on BPC-157 vs TB-500.

Two splits sold under one name

Both are claims about products, not a standard: no regulator or monograph defines "Wolverine", and only an assay shows what a given vial holds. The two splits put different amounts of TB-500 behind the same BPC-157 reading, so a volume or unit figure copied from one product does not transfer to the other. The other blends built on the same pair are worked on the GLOW page and in GLOW vs KLOW.

Concentration at each water volume, 5 mg / 5 mg vial

Each peptide's concentration = its milligrams ÷ millilitres of water. One unit on a U-100 syringe is 0.01 mL.

The last column is the figure the protocol pages lead with. It is the two peptide columns added together; neither peptide is present at that strength, so a reading worked from it delivers half the stated amount of each.

One number, two meanings

The two protocol pages read on 2026-10-05 both describe a 5 mg / 5 mg vial and both use the figure 250 mcg:

Page B's 5 units of a 5 mg/mL total solution is 0.05 mL × 5 mg/mL = 250 mcg of blend, which is 125 mcg of each peptide. A reader comparing the two pages sees the same number and draws twice the amount of each peptide on page A. A figure quoted for a blend is only readable with three things beside it: the split, the water, and whether it counts the blend or one peptide.

Units for a stated amount

Units = amount in mcg × mL of water ÷ (that peptide's mg in the vial × 10).

5 mg / 5 mg vial, sized to a BPC-157 amount (TB-500 always equal):

1 : 2 vial (5 mg BPC-157 / 10 mg TB-500 in 3 mL, as described): one unit holds 16.7 mcg of BPC-157 and 33.3 mcg of TB-500, so 250 mcg of BPC-157 is 15 units and carries 500 mcg of TB-500; 2 mg of TB-500 is 60 units and carries 1 mg of BPC-157.

Readings with a decimal fall between the 1-unit marks; at 1 mL a 125 mcg draw is 2.5 units, where one mark is 40% of the amount. More water spreads the same milligrams over more units and changes nothing else.

The ratio the vial locks in

Pages read for this site on 2026-09-18 state figures for the two peptides on different scales: BPC-157 at 250 to 500 mcg once or twice daily, TB-500 at 2 to 2.5 mg twice weekly (as recorded on the BPC-157 and TB-500 dosage pages). A 1 : 1 vial cannot follow both per draw:

Per week the totals can overlap — 4 mg of each from two 2 mg draws sits inside the 1.75 to 7 mg weekly range those BPC-157 figures add up to — but the amount per injection and the number of injections cannot both match. A 5 mg / 5 mg vial holds 5 mg of TB-500 in all, about one and a quarter weeks at 4 mg a week (arithmetic on this page). This is arithmetic about the vial, not a schedule; nothing on this page sets an amount or a frequency.

Draws per vial

Page B gives its vial as "~40 days"; 40 is the number of draws, and at the five a week it states that is eight weeks (arithmetic on this page). Draw counts do not depend on the water: the volume changes the reading, not how many draws the milligrams allow. The general mixing procedure is on Medibact's reconstitution how-to; the single-peptide arithmetic is on the BPC-157 reconstitution page, and the blend calculator works any other split.

What the record does and does not hold

No registered trial gives BPC-157 and TB-500 together: a ClinicalTrials.gov search on 2026-10-05 for both as interventions returned zero records. One page of each kind says the same in its own words — page A states that no controlled human trial "validates the combined subcutaneous schedule", and page B that the compound "has no peer-reviewed human dose-finding trials". The one experiment that combined them repaired the Achilles tendon in 32 male rats, eight per group, and gave BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, both, or nothing for four weeks; TB-500 alone reached significance on load to failure, and the authors report that the combination "did not confer additional benefits compared to either agent alone" (Biçer et al. 2026, PMID 42542926).

The registry itself needs reading with care. ClinicalTrials.gov returned four BPC-157 records and one TB-500 record on 2026-10-05. The TB-500 record (NCT07487363, sponsor listed as Hudson Biotech) opens its summary with "This fictional study is an example of a ClinicalTrials.gov-style record"; a BPC-157 record under the same sponsor name (NCT07437547) describes a 14-day hamstring trial with no dose posted. A registration is not evidence that a study exists or will report.

The arithmetic assumes each vial holds exactly its stated milligrams of each peptide and that both dissolve fully at the chosen volume; neither is shown without an assay. Nothing on this page is a dose, a volume to use or a schedule. The compound guides for BPC-157 and TB-500 are on the Medibact store.

Sources and dates

Opened 2026-10-05: two Wolverine protocol pages (one published 2026-03-04 and updated 2026-09-26, one undated) and a clinic page published 2026-03-24, quoted for the splits, water, draws and frequencies they state; PubMed abstract 42542926 (Biçer et al., Joint Dis Relat Surg 2026); ClinicalTrials.gov intervention searches for BPC-157, TB-500 and both together, and records NCT07487363 and NCT07437547. The single-peptide figures in circulation are as recorded on this site's BPC-157, TB-500 and BPC-157 vs TB-500 pages. Concentrations, readings and draw counts are arithmetic by this site. Corrections go to the contact page.